Table of Contents
WOBURN, Mass. — CutisPharma Inc. has been granted a patent regarding a method for the preparation, storage and dispensing of compounded suppositories.
The company said Wednesday that the U.S. Patent and Trademark Office has issued patent US 8,276,757 B2 for the method of suppository compounding for its FIRST container suppository mold.
Intended to be user-friendly and time-saving for pharmacists, the FIRST suppository mold is also customer-friendly because the take-home molds are designed to maintain the integrity of each suppository once compounded as well as to provide convenient patient dispensing, CutisPharma noted.
"The goal for CutisPharma and our FIRST Kits is to meet the ‘Golden Rule’ of compounding, which is one Rx from one prescriber for one patient, and our FIRST Kits will help pharmacies meet this goal," stated Dr. Indu Muni, founder, chairman and chief executive officer at CutisPharma.
"The use of FIRST Unit-of-Use Prescription Compounding Kits facilitates compliance with United States Pharmacopeia (USP) Chapter <795>," Muni added.
According to CutisPharma, it’s estimated that about 40 million retail and hospital outpatient prescriptions are prepared through compounding annually. About 1% of all prescriptions are compounded, and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion each year, the company reported.
FIRST products are designed to save dispensing time and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction, CutisPharma said. Using FIRST Kits, the pharmacist can compound a prescription faster than those prepared in the conventional way, and a single NDC number assigned for the entire kit facilitates the third-party reimbursement process and reduces audit-related adjustments, the company added.
CutisPharma now has 20 proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, six Magic Mouthwash kits, three omeprazole suspension kits and three lansoprazole suspension kits. Several more compounding kits are in the planning stages, the company said.
